The sac-4 gene of Neisseria gonorrhoeae and co-existing chlamydial infection

Citation for published version:
https://doi.org/10.1136/sti.76.5.400

Digital Object Identifier (DOI):
10.1136/sti.76.5.400

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Sexually Transmitted Infections

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
The *sac-4* gene of *Neisseria gonorrhoeae* and co-existing chlamydial infection

D J Phillips, C Patrizio, A Moyes, H Young

**Background/objectives:** Recently, the *sac-4* gene in *Neisseria gonorrhoeae* was postulated to increase the risk of developing mixed gonococcal and chlamydial infection. The aims of this study were to determine the frequency of the *sac-4* gene in a larger sample of isolates of different serovars and to assess the prevalence of *sac-4* in gonococcal isolates from patients with and without coexisting chlamydial infection.

**Methods:** Isolates from 259 episodes of gonorrhoea were tested by a PCR assay for the *sac-4* gene. The presence of co-existing chlamydial infection was determined from both laboratory and GUM clinical records.

**Results:** The overall prevalence of *sac-4* was 57.5% (149/259). The prevalence was not the same in all serovars and ranged from 34.9% in serovar 1B2 to 100% in serovar 1B18. Exact logistic regression analysis indicated significant differences in *sac-4* prevalence in isolates of different serovars. The prevalence of *sac-4* was 69.5% (41/59) in gonococcal isolates from patients with co-existing chlamydial infection compared with 57.9% (62/107) for those without chlamydial infection. Exact logistic regression analysis showed that the slightly increased *sac-4* prevalence among chlamydia positive patients (p>0.2) virtually disappeared when serovar status was taken into account (p>0.9).

**Conclusion:** The *sac-4* gene of the gonococcus does not increase the risk for mixed chlamydial infection.

(2000;76:400–402)

Keywords: dual infection; *Neisseria gonorrhoeae*; *Chlamydia trachomatis*; *sac-4*

**Introduction**

Dual infection of the genital tract with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* is well established with a prevalence ranging from 14–43% but little is known of the epidemiology and associated clinical features of such co-existing infections. Recently a gene, *sac-4*, was found in a high proportion of gonococcal isolates from patients with coexisting chlamydial infection and it was postulated that *sac-4* increased the risk of development of mixed gonococcal and chlamydial infection. This gene conferred stable (not lost on subculture) complement factor C1q dependent serum resistance in gonococci. The aims of this study were to use the polymerase chain reaction (PCR) assay described by Nowicki et al to determine the frequency of the *sac-4* gene in a larger range of isolates of different serovars; and to assess the prevalence of *sac-4* in gonococcal isolates from patients with and without coexisting chlamydial infection.

**Materials and methods**

**Patients and isolates**

Isolates from 259 episodes of gonorrhoea in 80 female and 179 male patients attending a genitourinary medicine (GUM) clinic were studied. The isolates represented 19 different serovars. The prevalence of *sac-4* was determined for each of the common serovars, arbitrarily defined as comprising more than 15 isolates each: serovars represented by less than 15 isolates were grouped together as “other 1A” and “other 1B” serovars (see table 1). The presence of coexisting chlamydial infection was determined from laboratory and GUM clinical records.

**Extraction of DNA and PCR assay**

The growth from an overnight plate culture was mixed with 1 ml of saline, centrifuged, resuspended in 200 µl of distilled water, and heated for 20 minutes at 100°C. After cooling and centrifugation the supernatant from each tube was stored at −20°C for PCR testing.

Primers were as described by Nowicki et al: Primer A, 5'TAT CTC GAG CAT CTC CTT TCC AAC C 3' Primer B, 5'TAG GAA TTC CTC TGA AGG TTA CGG 3'.

---

Scottish *Neisseria gonorrhoeae* Reference Laboratory, Department of Medical Microbiology, Edinburgh University Medical School, Teviot Place, Edinburgh EH9 9AG, UK

D J Phillips, C Patrizio, A Moyes, H Young

Correspondence to: Dr Hugh Young Hugh.Young@ed.ac.uk

Accepted for publication 18 July 2000

Table 1  Sac-4 prevalence in various gonococcal serovars isolated from patients with and without coexisting chlamydial infection

<table>
<thead>
<tr>
<th>Serovar</th>
<th>Overall</th>
<th>Known chlamydia positive patients*</th>
<th>Known chlamydia negative patients*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A2</td>
<td>80.2% (20/25)</td>
<td>69.2% (9/13)</td>
<td>100% (5/5)</td>
</tr>
<tr>
<td>Other 1A†</td>
<td>44.5% (8/18)</td>
<td>40% (2/5)</td>
<td>57% (4/7)</td>
</tr>
<tr>
<td>1B2</td>
<td>34.9% (22/63)</td>
<td>42.9% (9/21)</td>
<td>32.1% (9/28)</td>
</tr>
<tr>
<td>1B3</td>
<td>63.3% (19/30)</td>
<td>60% (2/12)</td>
<td>71.4% (10/14)</td>
</tr>
<tr>
<td>1B6</td>
<td>42.6% (20/47)</td>
<td>50% (2/1)</td>
<td>40.9% (9/22)</td>
</tr>
<tr>
<td>1B18</td>
<td>100% (16/16)</td>
<td>100% (7/7)</td>
<td>100% (8/8)</td>
</tr>
<tr>
<td>1B31</td>
<td>91.7% (33/36)</td>
<td>100% (4/4)</td>
<td>93.8% (15/16)</td>
</tr>
<tr>
<td>Other 1B‡</td>
<td>45.8% (11/24)</td>
<td>71.4% (5/7)</td>
<td>28.6% (2/7)</td>
</tr>
<tr>
<td>Total</td>
<td>57.5% (149/259)</td>
<td>69.5% (41/59)</td>
<td>57.9% (62/107)</td>
</tr>
</tbody>
</table>

*Chlamydia status was not known for 93 patients.
†18 isolates representing serovars 1A1, 1A4, 1A5, 1A6, 1A8, and 1A21.
‡24 isolates representing serovars 1B1, 1B4, 1B7, 1B8, 1B13, 1B23, and 1B32.
The sac-4 gene of Neisseria gonorrhoeae and co-existing chlamydial infection

A volume of 2 µl of DNA template was added to 100 µl reaction mix (50 mM KCl, 10 mM TRIS-HCl, 15 mM MgCl₂, and 0.1% Triton X-100) containing 0.5 units of Taq Polymerase (Promega Corporation, Southampton), 20 µmol of each DNTP (Promega), and 0.1 µmol of each primer (Oswel DNA Service, Southampton). The reaction mixture was overlaid with two drops of liquid paraffin. The amplification reaction consisted of 30 cycles of 1 minute denaturation at 92°C, 1 minute annealing at 55°C, and 1 minute extension at 72°C. An aliquot of 20 µl was removed for electrophoretic analysis on a 2% agarose gel. A band corresponding to 344 base pairs indicated a positive sac-4 result.

A sac-4 negative and positive control strain were included in each run.

STATISTICAL ANALYSIS

This was performed using exact logistic regression.

Results

PCR analysis showed that 149 isolates (57.5%) were sac-4⁺ (each strain gave a single band corresponding to 344 base pairs) and 110 isolates (42.5%) were sac-4⁻ (no bands present). An example of a typical gel is shown in figure 1. The prevalence of sac-4 ranged from 34.9% in serovar 1B2 to 100% in serovar 1B18 (table 1). The data in table 1 were analysed by exact logistic regression, with sac-4 as the response (dependent) variable, and chlamydia status and gonococcal serovar as independent (explanatory) factors with two and eight levels respectively. Comparing chlamydia positive with chlamydia negative patients unadjusted for serovar gave an odds ratio = 1.65, CI (0.8,3.47) p=0.2. This indicates that overall a higher prevalence of sac-4 was observed in gonococcal isolates from chlamydia positive patients than in isolates from chlamydia negative patients but the difference was not statistically significant. Comparing the prevalence of sac-4 in gonococcal isolates from chlamydia positive patients with chlamydia negative patients adjusted for gonococcal serovar gave an odds ratio = 1.06 CI (0.42,2.6) p>0.9. Thus the slight excess of sac-4 prevalence in gonococcal isolates from chlamydia positive patients virtually disappears when the serovar of the infecting gonococcal isolate is taken into account.

Comparing the effects of gonococcal serovar adjusted for the chlamydia status of the patient, the odds ratios compared with serovar 1A2 were: other 1A serovars 0.19 CI (0.01–1.44); 1B2 0.14 CI (0.01–0.74); 1B3 0.44 CI (0.06–2.29); 1B6 0.11 CI (0.002–1.06); 1B18 undefined (this group had 100% prevalence for sac-4); 1B31 4.34 CI 0.32–251.66); other 1B 0.33 (0.05–1.84). These results indicate significant differences in sac-4 prevalence between the serovar groups taking into account the chlamydia status of the patients. Exact logistic regression analysis for interaction between chlamydia status and gonococcal serovar yielded a p value of 0.05. Thus there is no evidence for differences between serovar groups in the comparison of sac-4 prevalences between the chlamydia positive and chlamydia negative patients.

Similar results were obtained using approximate logistic regression including the subjects with unknown chlamydia status.

Discussion

The majority of isolates, 57.5% (149/259) in our local population of gonococi, were sac-4 positive. However, the prevalence of sac-4 was not significantly higher (p=0.2) in gonococcal isolates from patients with coexisting chlamydial infection (69.5%) than in those without (57.9%). These findings suggest that sac-4 does not increase the risk of developing mixed infection with C trachomatis. Our findings differ from those of Nowicki et al who found sac-4 in 71% (10/14) of gonococcal strains isolated from patients with mixed gonococcal and chlamydial infection and 7% (1/14) in isolates from patients with gonococcal infection only. Using exact logistic regression analysis we have shown that there are significant differences in the prevalence of sac-4 between certain serovars.

Both epidemiological and biological factors may play a part in the occurrence of coexisting gonococcal and chlamydial infection. However our findings do not support a biological role for sac-4 in the development of mixed infection.

We are grateful to Hannah Wills for checking records for coexisting gonococcal and chlamydial infections and to Dr John Duffy, director of Statlab Statistical Laboratory, Department of
Mathematics and Statistics, University of Edinburgh for performing the statistical analysis.

Contributors: The study was designed by HY; CP set up the sac-4 PCR assay in the laboratory; DJP performed sac-4 testing of the isolates; AM performed serotyping and provided valuable comments in the development of the manuscript; DJP and HY were responsible for the analysis of the data and preparation of the manuscript.


